# Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs

> **NCT00137917** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 478 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Meningococcal serogroup B vaccine

## Key facts

- **NCT ID:** NCT00137917
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2003-06
- **Final completion:** 2003-06
- **Target enrollment:** 478 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00137917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00137917, "Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00137917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*